SkinBiotherapeutics inks first commercial deal

SkinBiotherapeutics inks first commercial deal

SkinBioTherapeutics PLC (LON:SBTX) has inked a commercial agreement for its skincare product with FTSE 100 specialty chemical company, Croda International Plc (LON:CRDA).

It secures the AIM listed life sciences group its first deal and also provides third-party validation of its technology.

Full financial terms were not revealed; however, SkinBioTherapeutics will received “tiered royalties” on sales of any products that result from the partnership.

The company will be working with Croda unit Sederma, which will design and manufacture “new unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market”.

“This deal offers the potential for SkinBiotix to be incorporated into some of the world’s biggest cosmetics brands, which was always the vision that we had for the technology,” said Dr Cath O’Neill, SkinBioTherapeutics’ chief scientific officer.

The agreement leaves the company free to pursue commercial applications in other sectors.

Sederma managing director Arnaud Fournial said his group had been drawn to SkinBiotix discovery because of its “solid scientific foundation”.

“We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market,” he explained.

For full article click here

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.